proteolysis, can be readily synthesized, and have favorable biophysical properties for detection by liquid chromatography (LC) and MS 8 . The SRMAtlas provides a rich, proteome-wide database for choosing peptides to use in assay development.
The current human proteome in UniProtKP/ Swiss-Prot consists of 20,277 annotated proteins. Kusebauch et al. 1 compiled proteotypic peptides for nearly all annotated proteins and for 14,677 known isoforms, high-frequency single-nucleotide polynucleotide (SNP) variants, N-glycosylated modifications, and pre-and pro-hormones. The peptides were identified both from existing empirical MS datasets and, for proteins with no empirical evidence (51% of the proteome), from prediction algorithms. They synthesized the resulting 166,174 peptides and obtained their SRM coordinates (m/z, fragmentation data, relative retention time, and optimal instrument parameters) on instruments from two vendors. In total, SRM coordinates were characterized for an impressive 99.7% of the human proteome, with three or more peptides generated for 95.4% of proteins.
To demonstrate the utility of their resource, the authors used SRM to profile relative changes in protein abundance in two perturbation experiments-one on the effect of inhibiting cholesterol synthesis and the other on the effect of docetaxel (Docefrez, Taxotere) on prostate cancer cell lines. In both cases, the results showed that the resource facilitates the use of SRM to confirm hypotheses.
SRMAtlas represents a first step in the process of developing targeted MS assays for any human, unmodified protein of interest. Biologists and clinical laboratories must now develop these assays for real-world samples and conditions (Fig. 1) . Simply having SRM coordinates does not guarantee that a peptide will be detected in real samples. For example, the MS signal from a protein of interest might be too low in biological samples for quantification by LC-SRM (indeed most selected enzymatic, nucleic acid or mass tag on the antibody-making the assays highly susceptible to interferences that compromise the specificity and accuracy of the measurements. Indeed, it is extremely difficult to identify antibodies that specifically bind a single protein in a range of biological specimens 5, 6 .
Because of these analytical limitations, protein quantification using SRM is gaining acceptance. Unlike untargeted 'shotgun' modes of MS, which are widely used in discovery experiments, SRM is performed on specialized instruments that can be tuned to detect analytes of interest in complex samples based on their mass-to-charge ratio (m/z). In contrast to global isobaric labeling strategies, SRM detects signature peptides that are unique to a protein of interest. A stable isotope-labeled version of each target peptide or protein is spiked into the sample at a known concentration to achieve precise, relative protein quantification.
As the mass spectrometer directly quantifies the actual analyte of interest rather than a surrogate signal, specificity is in general much improved over conventional immunoassays, even when SRM is coupled to antibody-based analyte enrichment. SRM assays can be highly multiplexed, are precise across more than three orders of magnitude, and can be standardized across laboratories 7 . Suitable mass spectrometers are widely available in clinical and academic core laboratories, where they have been used for decades to quantify small molecules (e.g., metabolites).
Although the technical infrastructure is in place, broad adoption of SRM has been slowed by the need to develop validated, quantitative assays and assay reagents for each protein to be measured. A quantitative assay is a highly characterized laboratory process for making reliable measurements of an analyte of interest. A crucial first step in assay development is the selection of proteotypic peptides that are unique to the protein of interest, are reproducibly released by Proteomics has long taken a backseat to genomics, hampered by the greater technical challenges of analyzing proteins rather than DNA. But thanks to recent advances in technology, it is now poised to become a standard tool in many areas of biological research. New approaches for targeted mass spectrometry (MS), such as selected reaction monitoring (SRM), also known as multiple reaction monitoring (MRM), are enabling precise protein quantification that can be highly multiplexed and standardized across laboratories. A proteomics resource published recently in Cell provides an entry point for investigators interested in applying SRM to particular proteins of interest. The SRMAtlas, by Kusebauch et al. 1 , includes SRM MS coordinates (signature peptides, fragments and retention times) for nearly all unmodified proteins in the human proteome-the basic translated products of all human genes. This knowledge base, when combined with the development of wellcharacterized assays, will make rigorous quantitative proteomic studies accessible to the wider research community.
Even in the era of genomics, quantifying proteins is important. Genomic and transcriptional profiles are not reliable predictors of protein levels or activity [2] [3] [4] , and proteins are the main targets of therapeutics. Quantification of proteins has traditionally been carried out using immunoassays (e.g., western blotting, immunohistochemistry, ELISA) that are difficult to multiplex and often semi-quantitative at best. Additionally, these assays rely on commercially available antibodies, up to half of which do not work as claimed 5 . Once the protein analyte is captured, its concentration is inferred from a surrogate signal-a fluorescent, peptides in SRMAtlas were not observed in empirical data). This is especially true for studies of complex matrices like plasma or cell lysates, in which many endogenous peptides must be enriched to be quantified by SRM. Furthermore, interferences (e.g., SRM signals that do not arise from the analyte of interest) can be encountered when applying SRM coordinates to complex biological matrices, so it is critical to confirm the specificity of the SRM signal to avoid artifacts.
Guidelines for developing well-characterized targeted MS-based assays, analogous to robust protocols in other areas of quantitative measurement, have been established by the community 9 . To have confidence in experimental results, basic performance metrics of the assay must be characterized, such as imprecision, repeatability, reproducibility, bias, linearity, limit of quantification, matrix effects and selectivity, and analyte stability 10 . An open-source repository of well-characterized targeted MS assays is available 11 (https://assays.cancer. gov/), as is open-source software for data analysis 12 . Integration of these tools will undoubtedly expand the toolbox for all biological researchers, improving the way we study, diagnose, and treat disease. The inclusion of post-translational modifications beyond N-glycosylation, such as phosphorylation, will also greatly broaden the utility of the database. Figure 1 Workflow for development and implementation of targeted MS assays. Proteotypic peptides uniquely representing proteins of interest can be identified from SRMAtlas, along with fragment ions arising from these peptides that can be monitored by SRM. The next step is to determine whether the selected peptide analytes can be detected by SRM in the biological matrix of interest (e.g., plasma, cell line or tissue lysates). If the peptides are present but not detected by SRM, additional analytical method development is required, such as chromatographic enrichment of the target peptide (e.g., affinity enrichment). Once a procedure is developed that enables peptide detection by SRM, stable isotope-labeled standards are developed and used to perform bioanalytical method validation of the assay using a fit-for-purpose approach in the biological matrix of interest. During assay deployment, quantitative rigor is maintained through the use of QA/QC standards. 
